Target General Infomation
Target ID
T69619
Former ID
TTDR00742
Target Name
Membrane copper amine oxidase
Gene Name
AOC3
Synonyms
HPAO; VAP-1; Vascular adhesion protein-1; AOC3
Target Type
Successful
Disease Atopic dermatitis [ICD9: 691.8, 692.9; ICD10: L00-L99]
Asthma [ICD10: J45]
Central nervous system disease [ICD10: G00-G99]
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63]
Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1]
Hypertension [ICD9: 401; ICD10: I10-I16]
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25]
Psoriasis [ICD9: 696; ICD10: L40]
Pulmonary disease [ICD9: 460-519; ICD10: J00-J99]
Vascular disease [ICD9: 325, 430-459; ICD10: G45-G46, I60-I95]
Function
Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion. Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis.
BioChemical Class
Oxidoreductases acting on CH-NH2 group of donors
UniProt ID
EC Number
EC 1.4.3.21
Sequence
MNQKTILVLLILAVITIFALVCVLLVGRGGDGGEPSQLPHCPSVSPSAQPWTHPGQSQLF
ADLSREELTAVMRFLTQRLGPGLVDAAQARPSDNCVFSVELQLPPKAAALAHLDRGSPPP
AREALAIVFFGRQPQPNVSELVVGPLPHPSYMRDVTVERHGGPLPYHRRPVLFQEYLDID
QMIFNRELPQASGLLHHCCFYKHRGRNLVTMTTAPRGLQSGDRATWFGLYYNISGAGFFL
HHVGLELLVNHKALDPARWTIQKVFYQGRYYDSLAQLEAQFEAGLVNVVLIPDNGTGGSW
SLKSPVPPGPAPPLQFYPQGPRFSVQGSRVASSLWTFSFGLGAFSGPRIFDVRFQGERLV
YEISLQEALAIYGGNSPAAMTTRYVDGGFGMGKYTTPLTRGVDCPYLATYVDWHFLLESQ
APKTIRDAFCVFEQNQGLPLRRHHSDLYSHYFGGLAETVLVVRSMSTLLNYDYVWDTVFH
PSGAIEIRFYATGYISSAFLFGATGKYGNQVSEHTLGTVHTHSAHFKVDLDVAGLENWVW
AEDMVFVPMAVPWSPEHQLQRLQVTRKLLEMEEQAAFLVGSATPRYLYLASNHSNKWGHP
RGYRIQMLSFAGEPLPQNSSMARGFSWERYQLAVTQRKEEEPSSSSVFNQNDPWAPTVDF
SDFINNETIAGKDLVAWVTAGFLHIPHAEDIPNTVTVGNGVGFFLRPYNFFDEDPSFYSA
DSIYFRGDQDAGACEVNPLACLPQAAACAPDLPAFSHGGFSHN
Drugs and Mode of Action
Drug(s) Hydralazine Drug Info Approved Hypertension [542349], [550666]
BTT-1023 Drug Info Phase 2 Psoriasis [524913]
Vapaliximab Drug Info Terminated Inflammatory disease [547592]
Inhibitor 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE Drug Info [551374]
6-hydroxydopa quinone Drug Info [551393]
FP-1102 Drug Info [543706]
LJP-1207 Drug Info [543706]
PSX-4206 Drug Info [543706]
PXS-4159 Drug Info [543706]
RTU-1096 Drug Info [543706]
Vapill Drug Info [543706]
Modulator Hydralazine Drug Info [556264]
VAP-1 Drug Info [543706]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
BioCyc Pathway Phenylethylamine degradation I
Spermine and spermidine degradation I
KEGG Pathway Glycine, serine and threonine metabolism
Tyrosine metabolism
Phenylalanine metabolism
beta-Alanine metabolism
Metabolic pathways
PANTHER Pathway Phenylethylamine degradation
PathWhiz Pathway Beta-Alanine Metabolism
References
Ref 524913ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health.
Ref 542349(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7326).
Ref 547592Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017603)
Ref 550666Drug information of Hydralazine, 2008. eduDrugs.
Ref 532422Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9.
Ref 543706(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767).
Ref 550071Clinical pipeline report, company report or official report of Huginonline.
Ref 551374The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
Ref 551393How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.